Oragenics News (AMEX:ONI)
| Latest Oragenics News Headlines | | Date | Time | Source | | | 01/16/2007 | 9:00AM | PRNUS | Oragenics Announces the Exercise of All Outstanding Warrants from December 2005 Private Financing Round
ALACHUA, Fla., Jan. 16 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that all outstanding warrants associated with its December 2005 private financing round have been exercised bringing a total of $832,500 into the company. When combined with existing cash, this additional funding, reduced by... More...>> |
| 12/11/2006 | 2:14PM | PRNUS | Oragenics Calls Outstanding Warrants From December 2005 Private Financing Round
ALACHUA, Fla., Dec. 11 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that it had met the conditions for early redemption of warrants associated with its December 2005 private financing round, and has issued notification to holders that the company has exercised its right to accelerate the expiration... More...>> |
| 12/05/2006 | 9:31AM | PRNUS | Oragenics Seeks Patent for Unique Gene Targets for Tuberculosis
ALACHUA, Fla., Dec. 5 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that it has filed a U.S. patent application covering a collection of 44 genes of Mycobacterium tuberculosis that are specifically induced during active infection of human patients. The identification of these gene targets offers... More...>> |
| 11/20/2006 | 8:00AM | PRNUS | Oragenics Finalizes Acquisition of the iviGene Corporation
ALACHUA, Fla., Nov. 20 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that it has acquired all of the outstanding shares of the iviGene Corporation, a privately held early-stage company focused on technologies related to infectious diseases, in a stock transaction for 185,186 shares of new Oragenics... More...>> |
| 11/15/2006 | 8:35AM | PRNUS | Oragenics to Pursue Licensing of its Oral Probiotic Mouthrinse Following Positive Clinical Results
ALACHUA, Fla., Nov. 15 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that, as a result of the positive data from the clinical trial for its groundbreaking oral probiotic mouthrinse, it was advising a number of consultancy groups to submit plans for the sale or license of this technology. This... More...>> |
| 10/16/2006 | 12:08PM | PRNUS | Oragenics Reports Positive Clinical Results with its Oral Probiotic Mouthrinse
ALACHUA, Fla, Oct. 16 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that the first of two sets of subjects has completed a clinical trial utilizing its proprietary oral probiotic product, Probiora3(TM). The trial was designed to determine safety and the effectiveness of the mouthrinse against... More...>> |
| 09/18/2006 | 1:00PM | PRNUS | Oragenics' Lead Antibiotic Kills Bacteria by a Novel Mechanism
ALACHUA, Fla., Sept. 18 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced that its scientists, in collaboration with research groups from Utrecht University and the University of Groningen, both in the Netherlands, and led by Dr. Eefjan Breukink, have identified a novel mechanism for killing bacteria by... More...>> |
| 08/07/2006 | 11:08AM | PRNUS | Oragenics' Announces Fourth U.S. Patent Issued for MU1140(TM)
ALACHUA, Fla., Aug. 7 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI), a biotechnology development company, announced that the US Patent office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company's exclusively licensed novel antibiotic peptide, MU1140(TM... More...>> |
| 07/13/2006 | 9:57AM | PRNUS | Four Dental Experts Join Oragenics' International Scientific Advisory Board
ALACHUA, Fla., July 13 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announces that Dr. Raman Bedi, Chairman of Oragenics' International Scientific Advisory Board, has enlisted four global dental experts to join Oragenics' International Scientific Advisory Board: Dr. Ayyaz Khan of Pakistan, Dr. Brian Mouatt of... More...>> |
| 07/05/2006 | 2:16PM | PRNUS | Oragenics Receives $600,000 from Exercised Warrants
ALACHUA, Fla., July 5 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI), a biotechnology development company, today announced that four parties who had been involved in recent equity-based financing rounds, including one member of the company's Board of Directors, have exercised stock warrants that, collectively... More...>> |
| 06/13/2006 | 9:00AM | PRNUS | Oragenics to Enter Clinic With Its Oral Probiotic Mouthrinse
ALACHUA, Fla., June 13 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today its plans to initiate a human study for its proprietary oral probiotic product, Probiora3(TM). Subject recruitment will begin within a month. The study is designed to determine the effects of the mouthrinse on oral health... More...>> |
| 05/24/2006 | 9:07AM | PRNUS | Oragenics to Present at the Dutton Associates' Health Sciences Small Cap Conference
ALACHUA, Fla., May 24 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that Robert T. Zahradnik, Ph.D., president and chief executive officer, will be presenting at the Dutton Associates' Health Sciences Small Cap Conference on May 31, 2006 at 11:20 am PT/2:20 pm ET at The St. Regis Hotel, San Francisco... More...>> |
| 05/15/2006 | 3:07PM | PRNUS | Oragenics' Lead Antibiotic Proves Effective in Animal Infection Model
ALACHUA, Fla., May 15 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that its lead antibiotic candidate, MU1140(TM)(TM), has shown promising efficacy in preclinical testing using a mouse sepsis model. The study was designed to evaluate the protective effect of MU1140 when administered by intravenous... More...>> |
| 05/02/2006 | 10:08AM | PRNUS | Oragenics Receives SBIR Grant, Seeks Patent for Novel Synthetic Chemistry Technology
ALACHUA, Fla., May 2 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that it has been awarded an SBIR Phase 1 grant from the National Science Foundation (NSF) for lantibiotic synthesis using the company's proprietary Differentially Protected Orthogonal Lanthionine Technology (DPOLT). Although the... More...>> |
| 04/05/2006 | 9:11AM | PRNUS | Oragenics Seeks Patent for Novel Agent to Treat Obesity
ALACHUA, Fla., April 5 /PRNewswire-FirstCall/ -- Oragenics, Inc. (AMEX:ONI) announced today that it has filed a U.S. patent application covering the intellectual property surrounding its small molecule anti-obesity agent, LPT3-04, and its analogs. As a natural substance, LPT3-04 is orally available and has an excellent... More...>> |
| 04/07/2005 | 7:00AM | PRNUS | Wall Street Network Airing Exclusive Audio Interviews With CHMS, ARTX, WPCS and ONI
Wall Street Network Airing Exclusive Audio Interviews With CHMS,
ARTX, WPCS and ONI
An In-Depth Article Based on a Recent Audio Interview With ALTI Is Also
Available Now at www.wallst.net
NEW YORK, April 7 /PRNewswire/ -- Angela Du, President of China Mobility
Solutions, Inc. (OTC:CHMS) (BULLETIN BOARD: CHMS) recently... More...>> |
|
|
|